Two oncogenes, MYCN and mutationally activated ALK (the most commonly mutated genes in primary neuroblastoma [34,35,36,37] and an attractive candidate for targeted therapy [38,39]), were expressed under control of the dopamine-beta-hydroxylase (dβh) promoter [33]. This evidence concerns the gene MYCN and neuroblastoma.